Wedge Capital Management L L P NC Sells 45,007 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wedge Capital Management L L P NC decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 23.8% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 143,778 shares of the biopharmaceutical company’s stock after selling 45,007 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Amicus Therapeutics were worth $1,173,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. HealthInvest Partners AB lifted its position in Amicus Therapeutics by 18.6% in the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock worth $3,076,000 after buying an additional 51,368 shares during the last quarter. Intech Investment Management LLC lifted its position in Amicus Therapeutics by 59.7% in the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 46,633 shares during the last quarter. Norges Bank bought a new stake in Amicus Therapeutics in the 4th quarter worth approximately $29,033,000. Renaissance Technologies LLC lifted its position in Amicus Therapeutics by 174.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company’s stock worth $19,863,000 after buying an additional 1,339,316 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Amicus Therapeutics by 35.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company’s stock worth $2,850,000 after buying an additional 79,602 shares during the last quarter.

Amicus Therapeutics Price Performance

FOLD opened at $6.11 on Wednesday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a 52-week low of $5.81 and a 52-week high of $12.65. The stock has a market capitalization of $1.88 billion, a PE ratio of -33.94, a price-to-earnings-growth ratio of 1.51 and a beta of 0.54. The stock’s 50 day moving average price is $6.54 and its 200-day moving average price is $8.40.

Analyst Ratings Changes

A number of equities analysts have commented on FOLD shares. UBS Group lifted their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Wells Fargo & Company decreased their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Wall Street Zen cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group decreased their price target on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.